Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Cash from Financing Activities (2022 - 2025)

Axsome Therapeutics (AXSM) has disclosed Cash from Financing Activities for 4 consecutive years, with $16.4 million as the latest value for Q4 2025.

  • Quarterly Cash from Financing Activities rose 15.03% to $16.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $101.5 million through Dec 2025, up 75.42% year-over-year, with the annual reading at $101.5 million for FY2025, 75.42% up from the prior year.
  • Cash from Financing Activities hit $16.4 million in Q4 2025 for Axsome Therapeutics, down from $21.3 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $246.1 million in Q2 2023 to a low of -$1.2 million in Q1 2024.
  • Historically, Cash from Financing Activities has averaged $48.4 million across 4 years, with a median of $29.8 million in 2024.
  • Biggest YoY gain for Cash from Financing Activities was 712300.0% in 2024; the steepest drop was 102.3% in 2024.
  • Year by year, Cash from Financing Activities stood at $1.1 million in 2022, then plummeted by 100.19% to -$2000.0 in 2023, then skyrocketed by 712300.0% to $14.2 million in 2024, then grew by 15.03% to $16.4 million in 2025.
  • Business Quant data shows Cash from Financing Activities for AXSM at $16.4 million in Q4 2025, $21.3 million in Q3 2025, and $34.5 million in Q2 2025.